MN HF1159

Increases Formulary Committee physician membership from four to at least five, with specific requirements for psychiatry, rare disease, pediatrics, and disability treatment expertise.

Increases consumer representatives on the committee from one to at least four, all of whom must have personal or professional connection to medical assistance, plus adds a representative from the Minnesota Rare Disease Advisory Council.

Increases required Formulary Committee meetings from twice per year to six times per year.

Extends the Formulary Committee expiration date from June 30, 2023 to June 30, 2027.

Requires public hearing before any drug deletion or modification to the preferred drug list, with analysis of impacts on public health and health disparities, plus mandates 45 days advance notice of Formulary Committee meetings and 30 days advance notice of drugs to be discussed.